Recombinant Human ANXA3 Protein (5-322 aa), His-tagged

ANXA3 has been implicated in several diseases and disorders. For instance, it has been identified as a potential biomarker for lung cancer and colorectal cancer. Additionally, ANXA3 may play a role in inflammation, atherosclerosis, and neuronal development.

Yes, ANXA3 has been implicated in the regulation of inflammation. It has been shown to interact with other proteins involved in the inflammatory response and can modulate the production of pro-inflammatory molecules. ANXA3 may also contribute to the resolution of inflammation by promoting anti-inflammatory processes.

Yes, genetic variations and mutations in the ANXA3 gene have been reported. Some of these variations have been associated with certain diseases or traits, such as a higher risk of atherosclerosis or altered red blood cell morphology. However, the functional implications of these variations and their precise connection to disease development are still being investigated.

Yes, ANXA3 can interact with various proteins to regulate specific cellular processes. For example, it can bind to actin and contribute to cell migration and membrane repair. It can also interact with other annexins or phospholipids to mediate membrane organization and vesicular trafficking.

Yes, ANXA3 expression can be regulated by various factors. For example, certain transcription factors, such as SP1 and NF-κB, can bind to the promoter region of ANXA3 and regulate its transcription. Additionally, epigenetic modifications, such as DNA methylation and histone acetylation, can also influence ANXA3 expression levels.

Besides cancer, ANXA3 has been implicated in the pathogenesis of other diseases and conditions, including autoimmune disorders, cardiovascular diseases, and neurological disorders. However, further research is needed to fully understand the mechanisms by which ANXA3 contributes to these conditions.

Yes, ANXA3 has been implicated in cancer progression. It is often overexpressed in various cancer types, including breast, lung, colon, and pancreatic cancer. ANXA3 can promote tumor growth, angiogenesis, and metastasis by modulating cell survival, proliferation, and invasion pathways. It has also been associated with chemoresistance in certain cancers.

ANXA3 is primarily localized in the cytoplasm of cells, but it can also be found associated with the plasma membrane or in the nucleus.

While ANXA3 is primarily known for its involvement in membrane organization and cellular processes, it has also been implicated in regulating cell proliferation and apoptosis. Studies have suggested that ANXA3 can modulate cell growth and survival by influencing various signaling pathways and interacting with other proteins involved in these processes.

Yes, ANXA3 has been found to be involved in cell migration and invasion, particularly in cancer cells. It can interact with proteins associated with cytoskeletal rearrangement and cell adhesion, facilitating the movement and invasion of cells in various biological processes, including cancer metastasis.

ANXA3 has been reported to interact with certain signaling pathways. It can modulate the activity of the Wnt/β-catenin pathway, which is implicated in cell proliferation and tissue homeostasis. ANXA3 may also be involved in the regulation of calcium signaling pathways.

ANXA3 has shown promise as a potential diagnostic marker for certain types of cancer, including lung cancer and colorectal cancer. Elevated levels of ANXA3 have been observed in the blood or tissue samples of patients with these cancers. However, further research is needed to validate its diagnostic utility.

Yes, ANXA3 has been found to interact with several signaling molecules and participate in various signaling pathways. It can activate the Akt/mTOR pathway, MAPK/ERK pathway, and PI3K/Akt pathway, among others. These interactions indicate that ANXA3 plays a role in cell signaling and can influence cell survival, proliferation, and differentiation.

Currently, there are no specific drugs or therapies that directly target ANXA3. However, given its potential involvement in cancer and other diseases, it is an area of ongoing research and may become a target for future therapeutic interventions.

ANXA3 has been proposed as a potential biomarker for cancer diagnosis and prognosis. Elevated levels of ANXA3 have been associated with poor prognosis in several cancer types, suggesting that it could serve as a prognostic indicator. ANXA3 expression levels in blood or tissue samples can also be used to distinguish cancer patients from healthy individuals.

The potential therapeutic targeting of ANXA3 is currently under investigation. Understanding its precise role and interactions in different diseases could help in developing targeted therapies. However, more research is needed to determine the feasibility and efficacy of targeting ANXA3 for therapeutic purposes.

ANXA3 protein is found in various tissues of the body, including the gastrointestinal tract, lungs, kidneys, and reproductive organs. It is also detected in certain cancers such as lung cancer and colorectal cancer.

Yes, ANXA3 is involved in various biological processes beyond cancer. It has been implicated in cell apoptosis, calcium ion regulation, membrane repair, exocytosis, and cellular differentiation. Further research is needed to fully elucidate the precise roles and functions of ANXA3 in these processes.